Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Dec;44(12):3302-5.
doi: 10.1128/AAC.44.12.3302-3305.2000.

Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus

Affiliations

Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus

T Chiller et al. Antimicrob Agents Chemother. 2000 Dec.

Abstract

There have been several reports that the activity of echinocandin antifungal agents is not affected or decreased in the presence of human sera. It is known that these drugs are bound >80% in animal and human sera. The activity of the echinocandin caspofungin (MK-0991), a 1,3-beta-D-glucan synthase inhibitor, against Aspergillus fumigatus with and without human sera was studied. Conidia of A. fumigatus in microtest plate wells formed germlings after overnight culture in RPMI 1640. Caspofungin was then added with or without serum, and the germlings were incubated at 37 degrees C for 24 h. Human serum (5%) in RPMI 1640 alone did not significantly inhibit the growth of A. fumigatus in vitro. Caspofungin in RPMI 1640 exhibited dose-dependent inhibition, with concentrations of 0.1 and 0.05 microg/ml inhibiting 24.9% +/- 10.4% and 11.7% +/- 3.6%, respectively (n = 10; P < 0.01). The addition of 5% human serum to caspofungin at 0.1 or 0.05 microg/ml increased the inhibition to 78.6% +/- 5.8% or 58.3% +/- 19.2%, respectively (n = 10; P < 0.01 versus controls and versus the drug without serum). Lower concentrations of serum also potentiated drug activity. The effect of human sera was further seen when using caspofungin that had lost activity (e.g., by storage) against A. fumigatus at 0.1 microg/ml. Inactive caspofungin alone demonstrated no significant inhibition of hyphal growth, whereas the addition of 5% human serum to the inactive drug showed 83% +/- 16.5% inhibition (n = 5; P < 0. 01). The restoration of activity of caspofungin was seen at concentrations as low as 0.05% human serum. In contrast to prior reports, this study suggests that human serum acts synergistically with caspofungin to enhance its inhibitory activity in vitro against A. fumigatus.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Dose response of caspofungin against germlings of A. fumigatus. Vertical axis, percent inhibition of hyphal growth; horizontal axis, concentrations of drug in RPMI 1640. The standard deviation (SD) is shown at the top of each bar.

Similar articles

Cited by

References

    1. Abruzzo G K, Flattery A M, Gill C J, Kong L, Smith J G, Pikounis V B, Balkovec J M, Bouffard A F, Dropinski J F, Rosen H, Kropp H, Bartizal K. Evaluation of the echinocandin antifungal caspofungin (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother. 1997;41:2333–2338. - PMC - PubMed
    1. Bartizal K, Gill C J, Abruzzo G K, Flattery A M, Kong L, Scott P M, Smith J G, Leighton C E, Bouffard A F, Dropinski J F, Balkovec J. In vitro preclinical evaluation studies with the echinocandin antifungal caspofungin (L-743,872) Antimicrob Agents Chemother. 1997;41:2326–2332. - PMC - PubMed
    1. Brummer E, Chauhan S D, Stevens D A. Collaboration of human phagocytes with LY 303366 for antifungal activity against Aspergillus fumigatus. J Antimicrob Chemother. 1999;43:491–496. - PubMed
    1. Brummer E, Kamei K, Miyaji M. Anticryptococcal activity of voriconazole against Cryptococcus var. gattii vs. var. neoformans; comparison with fluconazole and effect of human serum. Mycopathology. 1998;142:3–7. - PubMed
    1. Hadju R, Thompson R, Sundelof J G, Pelak B A, Bouffard F A, Dropinski J F, Kropp H. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872) Antimicrob Agents Chemother. 1997;41:2339–2344. - PMC - PubMed

Publication types